TY  - JOUR

T1  - Trastuzumab for the treatment of primary HER2-positive breast cancer in HER2-positive women: a single technology appraisal

JO  - Health Technology Assessment

UR  - https://doi.org/10.3310/hta13suppl1-01

PY  - 2009/06/01

AU  - Ward S

AU  - Pilgrim H

AU  - Hind D

ED  - 

DO  - DOI: 10.3310/hta13suppl1-01

PB  - National Institute for Health and Care Research

VL  - 13

IS  - Suppl 1

SP  - 1

EP  - 6

Y2  - 2025/11/04

ER  -